Affordable Access

deepdyve-link
Publisher Website

Enhanced osteoarthritis therapy by nanoengineered mesenchymal stem cells using biomimetic CuS nanoparticles loaded with plasmid DNA encoding TGF-β1.

Authors
  • Cai, Yu1, 2
  • Wu, Cuixi1
  • Ou, Qianhua1
  • Zeng, Muhui1, 2
  • Xue, Song1, 3
  • Chen, Jieli1
  • Lu, Yao1, 2, 4
  • Ding, Changhai1, 5, 6
  • 1 Clinical Research Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510282, China. , (China)
  • 2 Orthopedic Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510282, China. , (China)
  • 3 Department of Rheumatology and Immunology, Arthritis Research Institute, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230032, China. , (China)
  • 4 Guangdong Key Lab of Orthopedic Technology and Implant, Guangzhou, Guangdong, 510010, China. , (China)
  • 5 Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, Academy of Orthopedics, Southern Medical University, Guangzhou, Guangdong, 510630, China. , (China)
  • 6 Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, 7000, Australia. , (Australia)
Type
Published Article
Journal
Bioactive Materials
Publisher
KeAi Publishing
Publication Date
Jan 01, 2023
Volume
19
Pages
444–457
Identifiers
DOI: 10.1016/j.bioactmat.2022.04.021
PMID: 35574050
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Mesenchymal stem cells (MSCs) therapy shows the potential benefits to relieve clinical symptoms of osteoarthritis (OA), but it is uncertain if it can repair articular cartilage lesions - the main pathology of OA. Here, we prepared biomimetic cupper [email protected] ([email protected]) nanoparticles (NPs) loaded with plasmid DNA (pDNA) encoding transforming growth factor-beta 1 (TGF-β1) to engineer MSCs for enhanced OA therapy via cartilage regeneration. We found that the NPs not only promoted cell proliferation and migration, but also presented a higher pDNA transfection efficiency relative to commercial transfection reagent lipofectamine 3000. The resultant CuS/TGF-β[email protected] NP-engineered MSCs (termed CTP-MSCs) were better than pure MSCs in terms of chondrogenic gene expression, glycosaminoglycan deposition and type II collagen formation, favoring cartilage repair. Further, CTP-MSCs inhibited extracellular matrix degradation in interleukin-1β-induced chondrocytes. Consequently, intraarticular administration of CTP-MSCs significantly enhanced the repair of damaged cartilage, whereas pure MSCs exhibited very limited effects on cartilage regeneration in destabilization of the medial meniscus (DMM) surgical instability mice. Hence, this work provides a new strategy to overcome the limitation of current stem cell therapy in OA treatment through developing more effective nanoengineered MSCs. © 2022 The Authors.

Report this publication

Statistics

Seen <100 times